SMI

NIK SMI1 is an effective and selective NF-κB inducing kinase (NIK) inhibitor. It also inhibits NIK-catalyzed hydrolysis of ATP to ADP (IC50: 0.23±0.17 nM).

SMI-6860766 is a CD40-Traf6 interactions blocker that acts by ameliorating the complications of diet-induced obesity in mice.

(Z)-SMI-4a (TCS PIM-1 4a) is a selective ATP-competitive Pim-1 kinase inhibitor with an IC50 of 21 nM.

SMI-16a (PIM1/2 Kinase Inhibitor VI) , a cell-permeable thiazolidinedione compound, acts as an effective, ATP-competitive inhibitor against Pim-1/2 kinases (IC50: 150/20 nM) while exhibiting little or no activity against a panel of 57 other kinases (≤18% inhibition at 5 μM).

SMI481 (NPPM6748481) is the first small-molecule Sec14-like phosphatidylinositol transfer proteins (PITPs) inhibitor.

Saccharin 1-methylimidazole (SMI) is a general-purpose activator used for DNA and RNA synthesis.

TCS-PIM-1-4a (SMI-4a), a Pim inhibitor, blocks mTORC1 activity through activation of AMPK and kills a wide range of both myeloid and lymphoid cell lines (IC50=0.8-40 μM).

SMI-1074 is a ligand for a target protein used in PROTAC technology. It serves as a precursor for synthesizing compounds SMD-3236 and SMD-1087.

SMI-10B13 is an inhibitor of oncostatin M (OSM) with a dissociation constant (KD) of 6.6 μM. It effectively inhibits OSM-mediated STAT3 phosphorylation in T47D and MCF-7 cell lines, with IC50 values of 136 nM and 164 nM, respectively. SMI-10B13 demonstrates antitumor activity in a human breast cancer mouse model.

OSM-SMI-10B, a derivative of OSM-SMI-10, effectively inhibits Oncostatin M (OSM)-induced STAT3 phosphorylation in cancer cells when co-incubated with OSM [1].

(E/Z)-OSM-SMI-10B, a derivative of OSM-SMI-10, effectively decreases OSM-induced STAT3 phosphorylation in cancer cells when co-incubated with OSM (Oncostatin M).

p18SMI-21 is a novel INK4C inhibitor. It also specifically blocking the bioactivity of p18 protein.

p18SMI-41 is a novel INK4C inhibitor. It also specifically blocking the bioactivity of p18 protein.

p18SMI-22 is an INK4C inhibitor.

(S)-NIK SMI1 is the isomer of NIK SMI1 and can be used as a control compound in experiments. NIK SMI1 serves as a potent and selective inhibitor of NF-κB-inducing kinase (NIK), effectively blocking the NIK-catalyzed hydrolysis of ATP to ADP, with an IC50 of 0.23±0.17 nM.

OSMI-4 is a low nanomolar O-GlcNAc transferase (OGT) inhibitor (EC50 of 3 μM in cells) that can be used to study OGT inhibition in different human cell lines.

OSMI-1 is an O-GlcNAc transferase (OGT) inhibitor (IC50=2.7 μM) that is orally active and cell-permeable. OSMI-1 inhibits protein O-GlcNA acetylation without qualitatively altering cell-surface N- or O- linked glycans.

OSMI-3 is a potent and cell-permeable inhibitor of O-GlcNAc transferase (OGT) for the study of cancer and cardiovascular disease.

Tetrofosmin is a phosphine developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds.

(S)-OSMI 3 (Ent-OSMI-3) has anti-inflammatory and anti-tumour activity and can be used to study diabetes and neurodegenerative diseases.

Isomyosmine is an isomer of myosine that inhibits nitrate reductase, has potential antiviral activity, reduces oxidative stress, can promote plant health and increase productivity and yield. Isomyosmine inhibits the release of TNF-α and can be used to study inflammation and coronavirus infection related to oxidoreductase.

Diosmin (Venosmine) is a bioflavonoid that strengthens vascular walls.

Fosmidomycin sodium salt (FR-31564 sodium salt) is an anti-infective antibiotic with anti-malarial activity that inhibits both Gram-negative and Gram-positive bacteria.

OSMI-2 is a cell-permeable inhibitor of O-linked N-acetylglucosamine transferase (OGT).